Study #2024-0321
A phase 1, open-label, multicenter study of INCB160058 in participants with myeloproliferative neoplasms.
MD Anderson Study Status
Enrolling
Treatment Agent
INCB160058, Standard disease-directed therapy
Description
This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myeloproliferative Neoplasms
Study phase:
Phase I
Physician name:
Naveen Pemmaraju
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.